Jaguar Health Q4 2020 Earnings Report
Key Takeaways
Jaguar Health, Inc. reported its financial results for the year ended December 31, 2020, with Mytesi net sales reaching approximately $9.3 million and gross sales at approximately $20.4 million, marking increases of 64% and 148%, respectively, compared to the previous year. The company's net loss for the year was $33.8 million, a decrease from the $38.5 million loss in 2019.
Mytesi net sales increased by 64% year-over-year, reaching approximately $9.3 million.
Mytesi gross sales increased by 148% year-over-year, reaching approximately $20.4 million.
The company's net loss decreased by 12% year-over-year, from $38.5 million to $33.8 million.
Operating expenses increased by 4% year-over-year, primarily due to inducement expense related to the Series B Convertible Preferred Stock and Series 3 Warrants.